156 related articles for article (PubMed ID: 32815449)
41. Efficacy and Safety of Denosumab in Postmenopausal Women With Osteoporosis: A Meta-Analysis.
Gu HF; Gu LJ; Wu Y; Zhao XH; Zhang Q; Xu ZR; Yang YM
Medicine (Baltimore); 2015 Nov; 94(44):e1674. PubMed ID: 26554766
[TBL] [Abstract][Full Text] [Related]
42. Efficacy and safety of sodium RISedronate for glucocorticoid-induced OsTeoporosis with rheumaTOid arthritis (RISOTTO study): A multicentre, double-blind, randomized, placebo-controlled trial.
Fujieda Y; Horita T; Nishimoto N; Tanimura K; Amasaki Y; Kasahara H; Furukawa S; Takeda T; Fukaya S; Matsui K; Tsutsumi A; Furusaki A; Sagawa A; Katayama K; Takeuchi K; Katsumata K; Kurita T; Shane P; Kato M; Oku K; Yasuda S; Takahata M; Iwasaki N; Atsumi T
Mod Rheumatol; 2021 May; 31(3):593-599. PubMed ID: 32820698
[TBL] [Abstract][Full Text] [Related]
43. Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.
Zanchetta MB; Boailchuk J; Massari F; Silveira F; Bogado C; Zanchetta JR
Osteoporos Int; 2018 Jan; 29(1):41-47. PubMed ID: 28975362
[TBL] [Abstract][Full Text] [Related]
44. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
[TBL] [Abstract][Full Text] [Related]
45. The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease.
Ishiguro S; Ito K; Nakagawa S; Hataji O; Sudo A
Arch Osteoporos; 2017 Dec; 12(1):44. PubMed ID: 28425086
[TBL] [Abstract][Full Text] [Related]
46. Effects of denosumab on rheumatic diseases and refractory glucocorticoid-induced osteoporosis: a prospective study.
Ishida T; Yoshida S; Fujiki Y; Hata K; Kotani T; Takeuchi T
Arch Osteoporos; 2021 Feb; 16(1):39. PubMed ID: 33624165
[TBL] [Abstract][Full Text] [Related]
47. The clinical utility of TRACP-5b to monitor anti-resorptive treatments of osteoporosis.
Gossiel F; Ugur A; Peel NFA; Walsh JS; Eastell R
Osteoporos Int; 2022 Jun; 33(6):1357-1363. PubMed ID: 35102444
[TBL] [Abstract][Full Text] [Related]
48. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates.
Dore RK; Cohen SB; Lane NE; Palmer W; Shergy W; Zhou L; Wang H; Tsuji W; Newmark R;
Ann Rheum Dis; 2010 May; 69(5):872-5. PubMed ID: 19734132
[TBL] [Abstract][Full Text] [Related]
49. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
[TBL] [Abstract][Full Text] [Related]
50. Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients.
Ebina K; Hashimoto J; Shi K; Kashii M; Hirao M; Yoshikawa H
Osteoporos Int; 2014 Dec; 25(12):2755-65. PubMed ID: 25082556
[TBL] [Abstract][Full Text] [Related]
51. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study.
Sumida K; Ubara Y; Hoshino J; Mise K; Hayami N; Suwabe T; Kawada M; Imafuku A; Hiramatsu R; Hasegawa E; Yamanouchi M; Sawa N; Takaichi K
Osteoporos Int; 2016 Apr; 27(4):1441-1450. PubMed ID: 26525045
[TBL] [Abstract][Full Text] [Related]
52. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.
Miller PD; Pannacciulli N; Brown JP; Czerwinski E; Nedergaard BS; Bolognese MA; Malouf J; Bone HG; Reginster JY; Singer A; Wang C; Wagman RB; Cummings SR
J Clin Endocrinol Metab; 2016 Aug; 101(8):3163-70. PubMed ID: 27270237
[TBL] [Abstract][Full Text] [Related]
53. Effect of denosumab switched from bisphosphonates in preventing joint destruction in postmenopausal rheumatoid arthritis patients with anti-cyclic citrullinated peptide antibodies.
Mori Y; Izumiyama T; Kurishima H; Kamimura M; Baba K; Mori N; Itoi E
J Orthop Surg Res; 2021 Feb; 16(1):107. PubMed ID: 33541393
[TBL] [Abstract][Full Text] [Related]
54. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial.
Langdahl BL; Teglbjærg CS; Ho PR; Chapurlat R; Czerwinski E; Kendler DL; Reginster JY; Kivitz A; Lewiecki EM; Miller PD; Bolognese MA; McClung MR; Bone HG; Ljunggren Ö; Abrahamsen B; Gruntmanis U; Yang YC; Wagman RB; Mirza F; Siddhanti S; Orwoll E
J Clin Endocrinol Metab; 2015 Apr; 100(4):1335-42. PubMed ID: 25607608
[TBL] [Abstract][Full Text] [Related]
55. Four-Year Teriparatide Followed by Denosumab
Hirooka Y; Nozaki Y; Okuda S; Sugiyama M; Kinoshita K; Funauchi M; Matsumura I
Front Endocrinol (Lausanne); 2021; 12():753185. PubMed ID: 34646240
[TBL] [Abstract][Full Text] [Related]
56. Distinct biomarkers for different bones in osteoporosis with rheumatoid arthritis.
Tomizawa T; Ito H; Murata K; Hashimoto M; Tanaka M; Murakami K; Nishitani K; Azukizawa M; Okahata A; Doi K; Saito M; Furu M; Hamaguchi M; Mimori T; Matsuda S
Arthritis Res Ther; 2019 Jul; 21(1):174. PubMed ID: 31307521
[TBL] [Abstract][Full Text] [Related]
57. The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.
Makras P; Papapoulos SE; Polyzos SA; Appelman-Dijkstra NM; Anastasilakis AD
Bone; 2020 Sep; 138():115478. PubMed ID: 32534221
[TBL] [Abstract][Full Text] [Related]
58. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
[TBL] [Abstract][Full Text] [Related]
59. Denosumab for dialysis patients with osteoporosis: A cohort study.
Kunizawa K; Hiramatsu R; Hoshino J; Mizuno H; Ozawa Y; Sekine A; Kawada M; Sumida K; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Ubara Y; Takaichi K
Sci Rep; 2020 Feb; 10(1):2496. PubMed ID: 32051451
[TBL] [Abstract][Full Text] [Related]
60. The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids.
Saag KG; McDermott MT; Adachi J; Lems W; Lane NE; Geusens P; Stad RK; Chen L; Huang S; Dore R; Cohen S
Arthritis Rheumatol; 2022 Apr; 74(4):604-611. PubMed ID: 34535967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
